Q3 Spinraza math confounds analysts as Biogen beats on both lines
admin 24th October 2017 Uncategorised 0Spinraza took center stage on Biogen’s third-quarter earnings call—in part because analysts couldn’t square their math on sales of the spinal muscular atrophy medication.
More: Q3 Spinraza math confounds analysts as Biogen beats on both lines
Source: fierce